Skip to content
Vivimed Labs logo

Vivimed Labs

VIVIMEDLAB NSE
₹5.42 +0.10 (+1.88%)
P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹5.42 −21.18 −79.6% since 18 Dec 2025
Start ₹26.60

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
−65.20%
Debt to Equity
Not meaningful: shareholders’ equity is negative
EPS (TTM)
−₹21.28
Book Value
−₹29.98
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
Not meaningful: book value is negative
ROE
Not meaningful: shareholders’ equity is negative
Dividend Yield
0.00%
EBITDA
−₹152 Cr
52W High
₹29.40
52W Low
₹4.75
Day Range
₹5.22 – ₹5.42
Volume
14,555

Peer Comparison

Healthcare › Pharmaceuticals

Vivimed Labs peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Vivimed Labs (this company)
₹5.42—₹43 Cr—0.00%—−65.20%₹76 Cr−₹176 Cr
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.770.44%16.50%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

39 Weak

Data confidence 84/100

Category scores

Quality
24
Poor
Returns, margins, earnings quality 22% weight
Valuation
72
Strong
Cheap vs sector & own history 24% weight
Growth
5
Poor
Sales & profit trajectory 9% weight
Financial Health
10
Poor
Solvency, leverage, coverage 9% weight
Momentum
25
Poor
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

6
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -39.5% over past five years.
  • Promoter holding is low: 7.57%
  • Contingent liabilities of Rs.183 Cr.
  • Company has high debtors of 236 days.
  • Promoter holding has decreased over last 3 years: -13.4%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1225
OscillatorsStrong Bullish225
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
34.27
Neutral
MACD (12,26,9)
−0.20
Bearish
SMA (50)
6.17
Bearish
SMA (200)
6.42
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
10Y−25.59%
5Y−39.46%
3Y−27.93%
1Y−39.66%

Net profit

Net profit growth by window
10YTurned to loss
5YLoss widened by ₹104 Cr
3YLoss narrowed by ₹153 Cr
1YLoss widened by ₹144 Cr

Operating cash flow

Operating cash flow growth by window
10Y−25.60%
5Y−57.35%
3Y−38.86%
1YTurned positive

Operating margin· change in pp

Operating margin growth by window
10Y−234.52 pp
5Y−220.86 pp
3Y−117.14 pp
1Y−205.93 pp

Trailing twelve months: The last four quarters end with the latest fiscal year, which the 1Y column covers.

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,462 Cr
Mar 2018₹1,186 Cr
Mar 2019₹1,315 Cr
Mar 2020₹1,059 Cr
Mar 2021₹861 Cr
Mar 2022₹237 Cr
Mar 2023₹187 Cr
Mar 2024₹149 Cr
Mar 2025₹116 Cr
Mar 2026₹70.00 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹214 Cr
Mar 2018₹76.00 Cr
Mar 2019₹57.00 Cr
Mar 2020−₹109 Cr
Mar 2021−₹72.00 Cr
Mar 2022−₹68.00 Cr
Mar 2023−₹329 Cr
Mar 2024−₹45.00 Cr
Mar 2025−₹32.00 Cr
Mar 2026−₹176 Cr

Quarterly Results

₹ Cr

Results for the period ended Jun 2026 were due by 14 Aug 2026 and are not in this table yet.

VIVIMEDLAB quarterly results, ₹ crore
Particulars Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
37
35
34
41
39
29
25
37
26
21
21
16
12
Expenses
201
36
40
40
67
40
25
35
28
22
22
27
152
Operating Profit
−164
0
−6
1
−28
−11
−1
1
−2
0
−1
−11
−140
OPM %
−444%
−0.9%
−18%
3.1%
−74%
−37%
−2.6%
2.9%
−10%
−1.3%
−4.6%
−68%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
Other Income
1
0
2
0
8
0
0
0
4
0
0
0
6
Interest
9
11
12
13
−33
0
0
0
2
1
2
1
1
Depreciation
96
5
5
5
6
4
4
7
6
5
5
5
12
PBT
−268
−16
−20
−17
7
−15
−5
−6
−5
−5
−7
−17
−146
Tax %
−1%
0%
0%
−3%
21%
0%
0%
0%
2%
0%
0%
0%
0%
Net Profit
−266
−16
−20
−16
5
−15
−5
−6
−5.13
−5
−7
−17
−146
EPS (₹)
−32.08
−1.88
−2.45
−1.94
0.63
−1.84
−0.62
−0.72
−0.68
−0.66
−0.88
−2
−17.74

Profit & Loss

₹ Cr
VIVIMEDLAB profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
1,380
1,346
1,462
1,186
1,315
1,059
861
237
187
149
116
70
Expenses
1,156
1,111
1,057
971
1,135
1,049
830
245
374
182
129
222
Operating Profit
224
234
404
215
180
10
32
−8
−187
−33
−13
−152
OPM %
16%
17%
28%
18%
14%
1%
3.7%
−3.3%
−100%
−22%
−11%
−218%
Other Income
6
11
8
10
23
8
10
1
1
10
4
6
Interest
86
84
68
82
70
61
56
40
36
3
3
4
Depreciation
66
61
58
56
67
67
56
18
108
20
20
26
PBT
78
100
286
86
66
−109
−70
−65
−331
−46
−31.39
−175
Tax %
7%
16%
25%
11%
13%
0%
3%
4%
−1%
−1%
0%
0%
Net Profit
72
84
214
76
57
−109
−72
−68
−329
−45
−32
−175
EPS (₹)
8.9
10.33
26.41
9.44
6.95
−13.16
−8.67
−8.16
−39.62
−5.48
−3.85
−21.28
Div. Payout %
0%
0%
2%
4%
0%
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
VIVIMEDLAB balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
17
17
17
17
17
17
17
17
17
Reserves
479
505
718
885
602
493
415
348
23
−22
−52
−227
Borrowings
1,076
1,015
1,011
1,149
1,280
1,268
326
359
379
377
376
397
Other Liabilities
327
519
317
343
431
432
532
543
658
579
580
567
Total Liabilities
1,898
2,055
2,062
2,394
2,329
2,210
1,289
1,266
1,076
950
921
753
Fixed Assets
813
814
879
1,035
965
1,045
502
520
436
418
408
386
CWIP
90
94
76
65
122
89
60
40
21
21
17
18
Investments
3
3
3
3
3
86
199
199
199
168
168
181
Other Assets
992
1,144
1,104
1,290
1,239
990
529
507
421
343
328
170
Total Assets
1,898
2,055
2,062
2,394
2,329
2,210
1,289
1,266
1,076
950
921
753

Cash Flow

₹ Cr
VIVIMEDLAB cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
140
154
58
21
422
80
567
28
35
−24
−2
8
Investing
−107
−190
−68
−164
−89
−196
404
−16
−5
28
−5
−1
Financing
−42
41
35
186
−338
72
−1,015
−10
−34
−6
5
−6
Net Cash Flow
−8
4
25
44
−5
−44
−44
1
−3
−2
−1
1
Free Cash Flow
16
95
−11
−142
333
−33
1,084
11
30
−26
−6
7
CFO/OP
63
66
23
30
243
972
1,720
−352
−19
73
13
−5

Ratios

VIVIMEDLAB financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
88
50
85
99
86
46
134
145
203
233
236
Inventory Days
244
294
329
411
397
396
263
573
216
327
358
63
Days Payable
107
98
122
154
207
179
35
100
74
225
240
263
Cash Conversion Cycle
224
285
258
342
288
303
274
607
286
305
351
36
Working Capital Days
43
58
55
121
68
216
77
195
−15
−171
−255
−1,468
ROCE %
11%
12%
22%
9%
7%
−3%
−1%
−3%
−52%
−11%
−8%
−65%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vivimed Labs insights

69 extracted metrics across FY10–FY26.

Shareholding Pattern

As of Mar 2026

  • Public 68.75%
  • Others 21.91%
  • Promoters 7.57%
  • FIIs 1.64%
  • Government 0.12%

15.18% of promoter holding pledged as of Mar 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY20 concall · Aug 2019
    PPT
  • Concall · Mar 2019
    PPT
  • Concall · Nov 2018
    PPT
  • Q1 FY19 concall · Aug 2018
    PPT
  • Concall · Jun 2018
    PPT

Frequently Asked Questions about Vivimed Labs

What does Vivimed Labs Ltd do?
Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.
Where is Vivimed Labs Ltd (VIVIMEDLAB) listed?
Vivimed Labs Ltd trades as VIVIMEDLAB on the NSE and under code 532660 on the BSE.
Which sector does Vivimed Labs Ltd belong to?
Vivimed Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Vivimed Labs Ltd?
Over the last 52 weeks Vivimed Labs Ltd has traded between ₹4.75 and ₹29.4 as of 4 Nov 2026.

Company Information

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.

Website vivimedlabs.com
CEO Dr. Manohar Rao Varalwar
Employees 586
Listed 17 Aug 2005
Face Value ₹2

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/VIVIMEDLAB.md for Vivimed Labs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month